- AML diagnostics, covering a wide range of tests such as imaging, blood analysis, bone marrow biopsy, immunophenotyping, and genetic profiling, are essential in accurately diagnosing and classifying leukemia subtypes for effective treatment planning across various age groups
- The rising incidence of AML especially among individuals aged 65 and above alongside increasing awareness of hematological malignancies, and the growing demand for early-stage detection tools, is significantly fueling the global adoption of diagnostic solutions
- North America dominated the acute myeloid leukemia diagnostics market with the largest revenue share of 39% in 2024, supported by advanced healthcare infrastructure, high testing volumes across hospitals and cancer research institutes, and increasing use of molecular and biomarker-based tests, particularly in the U.S.
- Asia-Pacific is projected to be the fastest growing region in the acute myeloid leukemia diagnostics market during the forecast period due to improving diagnostic capabilities, growing patient populations, and expanded access through both direct tender and retail sales channels
- The consumables & accessories segment dominated the acute myeloid leukemia diagnostics market with a share of 55.8% in 2024, due to high usage frequency across independent diagnostic labs and imaging centers
